Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan's EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.
While Bluebird Bio stock doesn't look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.
We have been stalking Abbott Laboratories for an entry. With FDA clearance of its Alinity mobile blood test unit and recent pullback, now may be the time for an entry.
Exelixis stock has done a candle over candle reversal off of its uptrend line support which looks like a good swing trade setup. Exelixis stock popped with the FDA approval
Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level. Sorrento Therapeutics had a decline in short interest in the month of September. As of September 29th, there
Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a
Transenterix stock is coming off a 50 percent retracement after the stock exploded higher from FDA approval of its Senhance Robotic Surgical System. This is the first FDA surgical robotic
The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA
Mannkind Corporation stock has done a 38.2 percent Fibonacci Retracement on a new Buy rating on the stock. HC Wainwright picked up coverage of the stock and issued a Buy